Bente Langdahl

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Michael R. McClung, Andreas Grauer, Steven Boonen et al. · New England Journal of Medicine · 2014 · 1.2K citations

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Bente Langdahl, Cesar Libanati, Daria B. Crittenden et al. · The Lancet · 2017 · 450 citations

Bone Disease, Sclerostin, Bone Health +7

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Steven Boonen, Jean‐Yves Reginster, Jean‐Marc Kaufman et al. · New England Journal of Medicine · 2012 · 347 citations · Full text

Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure

Marianne Rix, Helle Frost Andreassen, Peter Claes Eskildsen et al. · Kidney International · 1999 · 310 citations · Full text

Hemodialysis, Urology, Renal Disease +12

A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density

Eric Orwoll, Christence Stubbe Teglbjærg, Bente Langdahl et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 224 citations · Full text